Urinary biomarkers of immunotherapy response and resistance published in Nature Biomedical Engineering

Our work on multiplexed protease activity sensors conjugated to checkpoint antibodies to discriminate early responses and resistance to immune checkpoint blockade was published in Nature Biomedical Engineering! Congratulations to Quoc, Anirudh, and the team! Read the full manuscript here.

Summary | Since 2014, the FDA has approved 7 immune checkpoint inhibitors, but not all patients benefit from therapy. We developed a new class of immune checkpoint inhibitor that is attached with protease sensors for early detection of drug treatment. In preclinical studies, we found that these therapeutic sensors can indicate early responses before future changes in tumor volume, and can identify different types of resistance as they emerge.

Press Coverage | Georgia Tech Research “Kwong lab develops biosensors for quick assessment of cancer treatment” | Inside Precision Oncology “Biosensors created to detect early response to immune checkpoint blockade” | MedicalXpress | Technology.org | EurekAlert! | ScienMag | Newswise | Bioengineer.org | The Medical News | Technology Networks | ecancer